TMN355 (Compound 3i) is a potent inhibitor of cyclophilin A (CypA) with IC50 of 1.52 nM and reduces foam cell formation and cytokine secretion. TMN355 is used for the treatment of atherosclerosis.

TMP195 (TFMO 2) is a selective, first-in-class, class IIa HDAC inhibitor with Ki of 59, 60, 26 and 15nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

TMP195 (TFMO 2) is a selective, first-in-class, class IIa HDAC inhibitor with Ki of 59, 60, 26 and 15nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

TMP195 (TFMO 2) is a selective, first-in-class, class IIa HDAC inhibitor with Ki of 59, 60, 26 and 15nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

TMP195 (TFMO 2) is a selective, first-in-class, class IIa HDAC inhibitor with Ki of 59, 60, 26 and 15nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

TMP195 (TFMO 2) is a selective, first-in-class, class IIa HDAC inhibitor with Ki of 59, 60, 26 and 15nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

TMP269 is a potent, selective class IIa HDAC inhibitor with IC50 of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

TMP269 is a potent, selective class IIa HDAC inhibitor with IC50 of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

TMP269 is a potent, selective class IIa HDAC inhibitor with IC50 of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively.

TMP778 is a selective inhibitor of RORγt with an IC50 of 5 nM in the Fluorescence Resonance Energy Transfer (FRET) assay and an IC50 of 17 nM in the RORγ assay.

TMPyP4 tosylate (TMP 1363), a quadruplex-specific ligand, inhibits the interaction between G-quadruplex (G4) and IGF-1 (Insulin-like growth factor type I). TMPyP4 tosylate is also a telomerase inhibitor with antitumor effects.

TMPyP4 tosylate (TMP 1363), a quadruplex-specific ligand, inhibits the interaction between G-quadruplex (G4) and IGF-1 (Insulin-like growth factor type I). TMPyP4 tosylate is also a telomerase inhibitor with antitumor effects.

TMZ(Temozolomide) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

TMZ(Temozolomide) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

TMZ(Temozolomide) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

TMZ(Temozolomide) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

Tobramycin (NSC 180514,Deoxykanamycin B, Nebramycin Factor 6) is an aminoglycoside antibiotic with an IC50 of 9.7 μM.

Tobramycin (NSC 180514,Deoxykanamycin B, Nebramycin Factor 6) is an aminoglycoside antibiotic with an IC50 of 9.7 μM.

Tobramycin sulfate is the sulfate salt of tobramycin, an aminoglycoside antibiotic derived from the bacterium Streptomyces tenebrarius with bactericidal activity.

Toceranib phosphate (Palladia, SU11654), the phosphate salt of toceranib, is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including Flk-1/KDR, PDGFR, and Kit with Ki values of 6 nM and 5 nM for Flk-1/KDR and PDGFRβ, respectively.

Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.

Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.

Tocilizumab (anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.

Tocofersolan (Tocophersolan) is a synthetic water-soluble version of vitamin E that is used in treatment of vitamin E deficiency.

Toddalolactone, a natural coumarin, inhibits the activity of recombinant human Plasminogen activator inhibitor-1 (PAI-1) in a dose-dependent manner, yielding an IC50 value of 37.31 ± 3.23 μM.

TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, TOFA is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. TOFA blocks fatty acid synthesis and induces cell death in a dose-dependent manner.

TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, TOFA is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. TOFA blocks fatty acid synthesis and induces cell death in a dose-dependent manner.

TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, TOFA is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. TOFA blocks fatty acid synthesis and induces cell death in a dose-dependent manner.

TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, TOFA is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. TOFA blocks fatty acid synthesis and induces cell death in a dose-dependent manner.

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1. Tofacitinib inhibits the expression of antiapoptotic BCL-A1 and BCL-XL in human plasmacytoid dendritic cells (PDC) and induced PDC apoptosis.

Tofacitinib citrate (CP-690550, Tasocitinib) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively. Tofacitinib citrate has anti-infection activity.

Tofacitinib citrate (CP-690550, Tasocitinib) is a novel inhibitor of JAK with IC50 of 1 nM, 20 nM and 112 nM against JAK3, JAK2, and JAK1, respectively. Tofacitinib citrate has anti-infection activity.

Tofogliflozin (CSG 452) is a novel sodium-glucose co-transporter 2(SGLT2) inhibitor with IC50 values of 2.9 nM and 8444 nM for hSGLT2 and hSGLT1, respectively.

Tofogliflozin (CSG 452) is a novel sodium-glucose co-transporter 2(SGLT2) inhibitor with IC50 values of 2.9 nM and 8444 nM for hSGLT2 and hSGLT1, respectively.

Tolbutamide (HLS 831) is an inhibitor of potassium channel, used for type II diabetes.